Artiva Biotherapeutics, Inc. (ARTV) 10-Year Financial Performance & Capital Metrics

ARTV • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutArtiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Show more

Revenue $251K -99.3%
EBITDA -$65M -128.3%
Net Income -$58M -111.2%
EPS (Diluted) -5.20 -337.0%
Gross Margin 100%
EBITDA Margin -25837.05% -30364.2%
Operating Margin -26805.58% -29171.0%
Net Margin -23303.98% -28080.8%
ROE -475.05%
ROIC -
Debt/Equity 0.08
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 94 (top 6%)
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-49.95%

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-18%

EPS CAGR

10Y-

5Y-

3Y-

TTM-18.47%

ROCE

10Y Avg-52.48%

5Y Avg-52.48%

3Y Avg-41.12%

Latest-46.37%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	2M	4.93M	33.49M	251K
Revenue Growth %	-	-	1.46%	5.79%	-0.99%
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	2M	4.93M	33.49M	251K
Gross Margin %	-	1%	1%	1%	1%
Gross Profit Growth %	-	-	1.46%	5.79%	-0.99%
Operating Expenses+	18.27M	55.27M	64.76M	64.16M	67.53M
OpEx % of Revenue	-	27.61%	13.13%	1.92%	269.06%
Selling, General & Admin	4.43M	12.86M	20.78M	13.91M	17.2M
SG&A % of Revenue	-	6.43%	4.21%	0.42%	68.55%
Research & Development	13.85M	42.41M	43.98M	50.25M	50.33M
R&D % of Revenue	-	21.18%	8.92%	1.5%	200.51%
Other Operating Expenses	0	0	0	0	0
Operating Income+	-18.27M	-53.27M	-59.83M	-30.67M	-67.28M
Operating Margin %	-	-26.61%	-12.13%	-0.92%	-268.06%
Operating Income Growth %	-	-1.92%	-0.12%	0.49%	-1.19%
EBITDA+	-18.2M	-53.02M	-58.67M	-28.41M	-64.85M
EBITDA Margin %	-	-26.49%	-11.9%	-0.85%	-258.37%
EBITDA Growth %	-	-1.91%	-0.11%	0.52%	-1.28%
D&A (Non-Cash Add-back)	73K	248K	1.16M	2.27M	2.43M
EBIT	-17.59M	-71.83M	-59.83M	-30.67M	-67.28M
Net Interest Income+	-197K	0	1.29M	2.54M	5.35M
Interest Income	2K	0	1.29M	2.54M	5.35M
Interest Expense	199K	0	0	0	0
Other Income/Expense	280K	-18.55M	1.49M	3.05M	8.79M
Pretax Income+	-17.99M	-71.83M	-58.34M	-27.62M	-58.49M
Pretax Margin %	-	-35.88%	-11.83%	-0.82%	-233.04%
Income Tax+	0	0	53K	72K	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-17.99M	-71.83M	-58.39M	-27.7M	-58.49M
Net Margin %	-	-35.88%	-11.84%	-0.83%	-233.04%
Net Income Growth %	-	-2.99%	0.19%	0.53%	-1.11%
Net Income (Continuing)	-17.99M	-71.83M	-58.39M	-27.7M	-58.49M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-1.02	-4.08	-3.32	-1.19	-5.20
EPS Growth %	-	-3%	0.19%	0.64%	-3.37%
EPS (Basic)	-1.02	-4.08	-3.32	-1.19	-5.20
Diluted Shares Outstanding	17.58M	17.58M	17.58M	23.28M	24.36M
Basic Shares Outstanding	17.58M	17.58M	17.58M	23.28M	24.36M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	26.11M	162.29M	104.67M	79.82M	188.63M
Cash & Short-Term Investments	25.44M	160.92M	102.53M	76.97M	185.43M
Cash Only	25.44M	160.92M	102.53M	53.5M	40.23M
Short-Term Investments	0	0	0	23.47M	145.19M
Accounts Receivable	0	468K	525K	1.76M	146K
Days Sales Outstanding	-	85.32	38.86	19.16	212.31
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	1.62M	1.09M	3.06M
Total Non-Current Assets+	3.13M	7.64M	28.37M	25.29M	20.95M
Property, Plant & Equipment	2.39M	4.08M	27.61M	24.64M	20.43M
Fixed Asset Turnover	-	0.49x	0.18x	1.36x	0.01x
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	732K	3.56M	762K	650K	525K
Total Assets+	29.23M	169.93M	133.05M	105.11M	209.58M
Asset Turnover	-	0.01x	0.04x	0.32x	0.00x
Asset Growth %	-	4.81%	-0.22%	-0.21%	0.99%
Total Current Liabilities+	5.76M	19.3M	25.63M	12.23M	12.25M
Accounts Payable	2.15M	1.44M	1.1M	614K	1.12M
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	1000K	0	0
Other Current Liabilities	0	0	0	0	0
Current Ratio	4.53x	8.41x	4.08x	6.53x	15.39x
Quick Ratio	4.53x	8.41x	4.08x	6.53x	15.39x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	45.04M	239.48M	248.13M	254.9M	10.69M
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	1.66M	1.31M	15.96M	13.32M	10.61M
Deferred Tax Liabilities	0	216.41M	216.41M	0	0
Other Non-Current Liabilities	43.38M	81K	115K	241.59M	73K
Total Liabilities	50.8M	258.78M	273.75M	267.13M	22.94M
Total Debt+	2.12M	1.74M	19.45M	16.91M	14.35M
Net Debt	-23.33M	-159.18M	-83.08M	-36.59M	-25.88M
Debt / Equity	-	-	-	-	0.08x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-91.81x	-	-	-	-
Total Equity+	-21.57M	-88.86M	-140.7M	-162.01M	186.64M
Equity Growth %	-	-3.12%	-0.58%	-0.15%	2.15%
Book Value per Share	-1.23	-5.05	-8.00	-6.96	7.66
Total Shareholders' Equity	-21.57M	-88.86M	-140.7M	-162.01M	186.64M
Common Stock	0	0	0	0	3K
Retained Earnings	-21.98M	-93.8M	-152.59M	-181.31M	-246.68M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	308K	-129K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.54M	-15.3M	-50.83M	-47.43M	-55.03M
Operating CF Margin %	-	-7.64%	-10.31%	-1.42%	-219.25%
Operating CF Growth %	-	-0.13%	-2.32%	0.07%	-0.16%
Net Income	-17.99M	-71.83M	-58.79M	-28.72M	-65.37M
Depreciation & Amortization	73K	248K	1.16M	2.27M	2.43M
Stock-Based Compensation	297K	4.31M	6.58M	7.05M	6.98M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	-278K	18.55M	4.08M	251K	1.25M
Working Capital Changes	4.36M	33.41M	-3.87M	-28.28M	-325K
Change in Receivables	0	-468K	-57K	-1.23M	1.61M
Change in Inventory	0	0	0	0	0
Change in Payables	1.82M	-1.24M	190K	-408K	519K
Cash from Investing+	-284K	-1.72M	-6.3M	-25.98M	-120.46M
Capital Expenditures	-284K	-1.72M	-6.3M	-3.26M	-642K
CapEx % of Revenue	-	0.86%	1.28%	0.1%	2.56%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	37.4M	152.75M	-1.26M	24.39M	162.23M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	-459K	-1.86M	-1.26M	24.4M	51K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-13.82M	-17.03M	-57.13M	-50.69M	-55.67M
FCF Margin %	-	-8.51%	-11.59%	-1.51%	-221.81%
FCF Growth %	-	-0.23%	-2.35%	0.11%	-0.1%
FCF per Share	-0.79	-0.97	-3.25	-2.18	-2.29
FCF Conversion (FCF/Net Income)	0.75x	0.21x	0.87x	1.71x	0.94x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	83K	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-475.05%
Gross Margin	-	100%	100%	100%	100%
Net Margin	-	-3587.66%	-1184.1%	-82.69%	-23303.98%
Debt / Equity	-	-	-	-	0.08x
Interest Coverage	-91.81x	-	-	-	-
FCF Conversion	0.75x	0.21x	0.87x	1.71x	0.94x
Revenue Growth	-	-	146.3%	579.21%	-99.25%

Frequently Asked Questions

Growth & Financials

Artiva Biotherapeutics, Inc. (ARTV) reported $0.3M in revenue for fiscal year 2024.

Artiva Biotherapeutics, Inc. (ARTV) saw revenue decline by 99.3% over the past year.

Artiva Biotherapeutics, Inc. (ARTV) reported a net loss of $72.3M for fiscal year 2024.

Dividend & Returns

Artiva Biotherapeutics, Inc. (ARTV) has a return on equity (ROE) of -475.1%. Negative ROE indicates the company is unprofitable.

Artiva Biotherapeutics, Inc. (ARTV) had negative free cash flow of $78.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener